PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.

Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).

PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes ...

Mubadala’s investment is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg ...